Aitchison, K. J. & Kerwin, R. W. (1997) Cost-effectiveness of clozapine. A UK clinic-based study. British Journal of Psychiatry, 171, 125–130.
Grace, J., Bellus, S. B., Raulin, M. L., et al (1996) Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatric Services, 47, 41–45.
Johnson, C. G., Littrell, R. N. & Macgill, A. H. (1994) Starting patients on clozapine in a partial hospitalisation programme. Hospital and Community Psychiatry, 45, 264–268.
Kane, J., Honingfield, G., Singer, J., et al (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789–796.
Kerwin, R. & Lofts, F. (1993) Clozapine in the management of schizophrenia. All schizophrenic patients would benefit. BMJ, 307, 199–200.
Novartis (2001) Clozaril®. Summary of Product Characteristics. Camberley: Novartis Pharmaceuticals UK.
Percudani, M., Fattore, G., Galletta, J., et al (1999) Health care costs of therapy – refractory schizophrenic patients treated with clozapine: a study in a community psychiatric service in Italy. Acta Psychiatrica Scandinavica, 99, 274–280.
Rosenheck, R., Cramer, J., Xu, W., et al (1997) A comparison of clozapine and haloperidol in hospitalised outpatients with refractory schizophrenia. New England Journal of Medicine, 337, 809–815.
Stein, L. & Test, M. A. (1980) Alternative to mental hospital treatment. (1) Conceptual model, treatment program, and clinical evaluation. Archives of General Psychiatry, 37, 392–397.